26 August - 1 September 2017
These are links to news stories from the last week that may be of interest to people in the UK. The link beneath each item will take you to the original story.
Please note that the MS Trust did not write the original items and does not endorse their content nor any claims made in them.
To keep up to date on all the latest news, views and research on multiple sclerosis, sign up for Open Door, our free newsletter or regular email alerts
Benefits changes affecting people with MS
The MS Society estimates that people with MS have lost over £6million in benefits due to being moved from the higher rates of Disability Living Allowance (DLA) to lower rates of Personal Independence Payment (PIP). The cut in benefits affected one in three people being reassessed. The government say that a third more people with MS are getting the higher rate of PIP than of DLA
MS Trust link: Benefits
South Korean court sees MS as an occupational disease
The South Korean Supreme Court has found in favour of a former employee at Samsung who claims her MS was caused by working in their factory. The Court cited the "high level of physical and mental stress in her job, long working hours, everyday use of a chemical, possible exposure to other chemical substances used on nearby assembly lines, and a lack of a family history of the disease".
Source: Daily Mail
MS Trust link: Causes of MS
Glandular fever and risk of MS
A US study found that people who have had mononucleosis (glandular fever), which is cause by the Epstein-Barr virus, have a higher risk of MS. This risk occured equally in white, black and Hispanic people
MS Trust link: Epstein-Barr virus (EBV)
Tecfidera after Tysabri
A small Italian study found that Tecfidera (dimethyl fumarate) was an effective treatment for people who have stopped taking Tysabri (natalizumab). This contrasts with previous studies, but the researchers suggest their success was due to a shorter (one month) washout period
Source: MS News Today
MS Trust link: MS Decisions - a guide to the disease modifying drugs for relapsing remitting MS